A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test if the addition of botensilimab to standard
chemotherapy improves the efficacy compared to just chemotherapy alone in participants with
metastatic pancreatic cancer. One group of participants will only receive chemotherapy while
a second group of participants will receive botensilimab and chemotherapy.